Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517021 · ClinicalTrials.gov registry record · Phase 3
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
A Phase 3 study, sponsored by Helsinn Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
NCT02517021 is a Phase 3 study that has completed, run by Helsinn Healthcare. The registered enrollment target is 405 participants.
The verdict
NCT02517021, a Phase 3 study, has completed, sponsored by Helsinn Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
Study Summary
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Interventions
- DRUG Dexamethasone
- DRUG Pro-netupitant/Palonosetron
- DRUG Netupitant/Palonosetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02517021
The ClinicalTrials.gov registry entry for NCT02517021 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Healthcare, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02517021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02517021 about?
NCT02517021 is a clinical study titled "A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting". NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repe...
What is the current status of trial NCT02517021?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2015-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02517021?
The interventions under investigation include: Dexamethasone (DRUG), Pro-netupitant/Palonosetron (DRUG), Netupitant/Palonosetron (DRUG).
Who is sponsoring clinical trial NCT02517021?
This trial is sponsored by Helsinn Healthcare, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.